Premium
Norethisterone and Gestational Diabetes
Author(s) -
Beischer Norman A.,
Cookson Toni,
Sheedy Mary,
Wein Peter
Publication year - 1992
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1992.tb01954.x
Subject(s) - norethisterone , medicine , gestational diabetes , obstetrics , diabetes mellitus , pregnancy , gestation , incidence (geometry) , endocrinology , population , health services , physics , environmental health , biology , optics , genetics
Summary: In a single practice during the 21 years 1971–1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p< 0.001). Gestational diabetes was no less severe (degree of hyper‐glycaemia, need for insulin therapy) when associated with norethisterone. However, follow‐up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance. Mascu‐linization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment. Norethisterone in these 69 pregnanices accounted for 33.3% (5 of 15) cases of clitoral hypertrophy diagnosed in 100,756 consecutive 1 births.